Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst insights, and future rally potential.

Medicus Pharma offers high-risk, high-reward potential, with its novel SkinJect patch for basal cell carcinoma and Antev ...

Health and Human Services Secretary Robert F. Kennedy Jr. lambasted federal agencies he accused of being overly influenced by ...

Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive ...

After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...

The pharma launch environment has changed extensively over the last decade. Sarah Rickwood discusses the increased payer power and the move towards targeted product launches in this article, as ...

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study ...

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

"I think the common thread is probably that there's a person that's been victimized or discarded or forgotten about by a ...

Driven by attractive margins and significant growth potential, the Indian diagnostics sector has emerged as a preferred bet ...

While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development continue to face a multitude of obstacles, such as complex methodologies, high ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...